Home | Contact Us | FAQ | Search & Site Map | Link to Us
Sign In | Join | Other 45 Sites in Network
Home
Discussion Groups
General
GeneralCardiologyVisionDentistryPharmacyLaboratoryNutritionAlternative
Diseases and Disorders
AIDSAlzheimer'sArthritisAsthmaCancerBreast CancerDiabetesEpilepsyGlaucomaHepatitisHerpesLupusProstate BPHProstate CancerProstatitisSinusitisTinnitus

Medical Forum / Diseases and Disorders / Alzheimer's / April 2005

Tip: Looking for answers? Try searching our database.

Cholesterol drugs and Alzheimers??

Thread view: 
Enable EMail Alerts  Start New Thread
Thread rating: 
genileuqcaj@aol.com - 21 Apr 2005 05:15 GMT
Are there any scientific studies that link cholesterol drugs (Lipitor,
Zocor, ect) as a cause of Alzheimers?  My mother is taking Lipitor.  My
father seems to think it is the reason for her dementia.  Mom takes
several medications for various conditions, and her medications are
covered by her insurance.  But my father is uncomfortable giving Mom
any medicines, even though he knows what happens when she doesn't get
one or more of her medicines.  Dad seems to think everything can be
cured with an herbal supplement, and receives several "alternative
medicine" journals in the mail.  (I'm not bashing alternative medicine
as a whole.  But the publications he receives can be very
misleading....)

Any help would be appreciated!
Dr. Harman - 21 Apr 2005 14:47 GMT
Atorvastatin-induced activation of Alzheimer's alpha secretase is
resistant to standard inhibitors of protein phosphorylation-regulated
ectodomain shedding.

Parvathy S, Ehrlich M, Pedrini S, Diaz N, Refolo L, Buxbaum JD, Bogush
A, Petanceska S, Gandy S.

Farber Institute for Neurosciences of Thomas Jefferson University,
Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania 19107,
USA. samgandy@earthlink.net

Studies of metabolism of the Alzheimer amyloid precursor protein (APP)
have focused much recent attention on the biology of juxta- and
intra-membranous proteases. Release or 'shedding' of the large APP
ectodomain can occur via one of two competing pathways, the alpha- and
beta-secretase pathways, that are distinguished both by subcellular
site of proteolysis and by site of cleavage within APP. The
alpha-secretase pathway cleaves within the amyloidogenic Abeta domain
of APP, precluding the formation of toxic amyloid aggregates. The
relative utilization of the alpha- and beta-secretase pathways is
controlled by the activation of certain protein phosphorylation signal
transduction pathways including protein kinase C (PKC) and
extracellular signal regulated protein kinase [ERK/mitogen-activated
protein kinase (MAP kinase)], although the relevant substrates for
phosphorylation remain obscure. Because of their apparent ability to
decrease the risk for Alzheimer disease, the effects of statins (HMG
CoA reductase inhibitors) on APP metabolism were studied. Statin
treatment induced an APP processing phenocopy of PKC or ERK activation,
raising the possibility that statin effects on APP processing might
involve protein phosphorylation. In cultured neuroblastoma cells
transfected with human Swedish mutant APP, atorvastatin stimulated the
release of alpha-secretase-released, soluble APP (sAPPalpha). However,
statin-induced stimulation of sAPPalpha release was not antagonized by
inhibitors of either PKC or ERK, or by the co-expression of a dominant
negative isoform of ERK (dnERK), indicating that PKC and ERK do not
play key roles in mediating the effect of atorvastatin on sAPPalpha
secretion. These results suggest that statins may regulate
alpha-secretase activity either by altering the biophysical properties
of plasma membranes or by modulating the function of as-yet
unidentified protein kinases that respond to either cholesterol or to
some intermediate in the cholesterol metabolic pathway. A
'phospho-proteomic' analysis of N2a cells with and without statin
treatment was performed, revealing changes in the phosphorylation state
of several protein kinases plausibly related to APP processing. A
systematic evaluation of the possible role of these protein kinases in
statin-regulated APP ectodomain shedding is underway.
Karen - 22 Apr 2005 03:02 GMT
When my MIL was diagnosed,  they discontinued Lipitor to make sure it wasn't
causing Alzheimer's type symptoms but I can't cite any studies.  We told
Hubby's cardiologist about that and about our concern of drug interactions
and he recommended Hubby use Benacol and see if it would work before trying
any statins.  Benacol is a butter substitute that tastes good and seems very
expensive until you look at it in the same light as a drug.  You have to get
1 tablespoon 3 x day and they have capsules if you aren't eating something
you would butter (like chinese food).  It work on Hubby and his cholesterol
came down from 385 to under 200 (with no side effects).  Apparently, it
works so well the FDA was looking at controlling it awhile back (saw it in
the paper) but I think they decided not to.

It might be worth a monitored try.  And yes, alternative medicine can be
good or a crock and it's hard for many people to discern which.

Karen

> Are there any scientific studies that link cholesterol drugs (Lipitor,
> Zocor, ect) as a cause of Alzheimers?  My mother is taking Lipitor.  My
[quoted text clipped - 9 lines]
>
> Any help would be appreciated!
Sharon Hope - 22 Apr 2005 04:10 GMT
Absolutely Lipitor and the other cholesterol lowering statin drugs are known
to cause memory loss much like Alzheimers - with symptoms close enough that
many doctors are confused into thinking it is Alzheimers.

Get in contact with the UCSD Statin Study, a National Institutes of Health
(NIH) funded study immediately.
http://medicine.ucsd.edu/statin/contactinfo.html

See also Dr. Graveline's website for his book "Lipitor, Thief of Memory,"
and his new book, "Statin Drugs Side Effects." http://www.spacedoc.net/

Do not delay, get the information to her doctor, and if the doctor will not
listen, find a different doctor who will.  It can take many months to years
to recover from statin cognitive damage.

My own husband took Lipitor 10 mg for 4 years, and developed all 3 of the
most common serious side effects: Cognitive damage (Memory loss, and
transient global amnesia and aphasia), muscle pain, and peripheral
neuropathy.  He was in his mid-50's, a successful CEO, until the Lipitor
damage - his short-term memory loss was so bad that he measured below the 1
percentile in Neuropsych testing.  He has been in cognitive rehabilitation
therapy for 3 years off the Lipitor and has improved, but not fully
recovered yet.

Statin adverse effects are documented, and the serious damage can be
preventable - if doctors would only monitor for them.  Typically, they not
only do not monitor for statin memory loss, they deny it, delaying the
remedy and deepening the damage.

Be certain the doctor files an adverse effects report with the FDA, and
fills in the questionnaire for the Statin Study.  It is just wrong that a
patient be harmed to the degree that this degree of memory loss is obvious
to the family, and they need to learn about it on an internet news group.

More info to take to the doctor:
Statin Adverse Effects FAQ: MEMORY LOSS & STATINS, AMNESIA & STATINS

To my physician,

I believe that my symptoms may be due to the adverse effects associated with
cholesterol-lowering statin drugs.  I need your help to understand the cause
of my symptoms, treatment options, and the prognosis for my recovery.

Please review the references below, published medical studies that show
similar problems associated with statin drugs.  These are made available via
the National Institutes of Health (NIH, http://www.ncbi.nlm.nih.gov/Entrez/)
library of biomedical journal citations and other major repositories of
medical research.

Also, I am respectfully requesting that you file an adverse effects report
with the FDA (http://www.fda.gov/medwatch/how.htm), and that you please send
a copy of the report to the to the NIH-funded Statin Study, attention: Dr.
Beatrice Golomb, Principal Investigator.
Statin Study website: http://medicine.ucsd.edu/statin/
Statin Study contact info: http://medicine.ucsd.edu/statin/contactinfo.html
UCSD STATIN STUDY E-MAIL ADDRESS: statinstudy@ucsd.edu
MAILING ADDRESS: UCSD Statin Study 9500 Gilman Dr. La Jolla, CA 92093-0995
PHONE NUMBER: (858) 558-4950

Thank you

MEMORY LOSS & STATINS, AMNESIA & STATINS

References (updated as of  January 7, 2005):

Randomized trial of the effects of simvastatin on cognitive functioning in
hypercholesterolemic adults.Am J Med. 2004 Dec 1;117(11):823-9. Muldoon MF,
Ryan CM, Sereika SM, Flory JD, Manuck SB.Center for Clinical Pharmacology,
University of Pittsburgh, Pennsylvania 15260, USA. mfm10@pitt.edu"This study
provides partial support for minor decrements in cognitive functioning with
statins. Whether such effects have any long-term sequelae or occur with
other cholesterol-lowering interventions is not known." This is the second
of two studies by Muldoon, both showing measurable cognitive decline in
statin groups after only 6 months, using Neuropsychological (NP) testing.
Further, this study identifies the subset of NP tests that are "statin
sensitive" in detecting the cognitive deficits.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15589485


Effects of lovastatin on cognitive function and psychological well-being.

Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, Manuck
SB.
After 6 months, 100% of the patients on placeboes showed a measurable
increase in cognitive function, while the statin patients showed a
measurable decrease in cognitive function in some areas.
Am J Med. 2000 May;108(7):538-46.
PMID: 10806282 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
0806282&dopt=Abstract


Cognitive impairment associated with atorvastatin and simvastatin.King DS,
Wilburn AJ, Wofford MR, Harrell TK, Lindley BJ, Jones DW.Department of
Medicine, University of Mississippi Medical Center, Jackson, Mississippi
39216, USA. dking@pharmacy.umsmed.eduPharmacotherapy. 2003
Dec;23(12):1663-7. "we report two women who experienced significant
cognitive impairment temporally related to statin therapy. One woman took
atorvastatin, and the other first took atorvastatin, then was rechallenged
with simvastatin. Clinicians should be aware of cognitive impairment and
dementia as potential adverse effects associated with statin therapy."
PMID: 14695047
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=14695047


"DRUGS THAT MAKE YOU FORGET"
Australian Adverse Drug Reactions Bulletin (Australia's equivalent to the
FDA)
Volume 17, Number 3, August 1998, section 3, page 3
Simvastatn is listed under "DRUGS THAT MAKE YOU FORGET"
Recognizing the 14 reports of Amnesia under that drug, .8% of the total
adverse effects for that drug.
www.health.gov.au/tga/docs/pdf/aadrbltn/aadr9808.pdf

Statin-associated memory loss: analysis of 60 case reports and review of the
literature.
Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM.
Drug Information Service, Duke University Medical Center, Durham, North
Carolina 27710, USA.  Pharmacotherapy. 2003 Jul;23(7):871-80.

This study searched the MedWatch drug surveillance system of the Food and
Drug Administration (FDA) from November 1997-February 2002 for reports of
statin-associated memory loss. They also reviewed the published literature.
References from the study are good for follow-up research.

Abstract:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
2885101&dopt=Abstract


Full Study Text free on Medscape:

http://www.medscape.com/viewarticle/458867

The Role of Lipid-Lowering Drugs in Cognitive Function: A Meta-Analysis of
Observational Studies

from Pharmacotherapy
Posted 06/30/2003

Mahyar Etminan, Pharm.D., Sudeep Gill, M.D., FRCPC, Ali Samii, M.D., FRCPC

Although this study does bring the cognitive issues to light, it is a very
poor study.  The authors left out the pivotal study by Dr. Muldoon, that
showed 100% of statin users had a  measurable loss of cognitive ability
after 6 months, while 100% of the placebo group improved their scores.

Abstract:

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
2820814&dopt=Abstract


Full Study Text free on Medscape:

http://www.medscape.com/viewarticle/456866

Simvastatin-Associated Memory Loss
Amanda Orsi, Pharm.D., Olga Sherman, Pharm.D., and Zegga Woldeselassie,
Pharm.D.,
Abstract: The statins are widely used to treat dyslipidemias. They are
generally associated with mild adverse effects, but rarely, more serious
reactions may occur. A 51-year-old man experienced delayed-onset,
progressive memory loss while receiving simvastatin for
hypercholesterolemia. His therapy was switched to pravastatin, and memory
loss resolved gradually over the next month, with no recurrence of the
adverse effect.
from Pharmacotherapy
Posted 06/01/2001
Page 1 of 3:
http://www.medscape.com/viewarticle/409738?WebLogicSession=PXke2H8h99pyNVSCajAh5
clptzOAHJSZuNBobSwWmi9veWjdJ2A3%7C-1468812056489609316/184161392/6/7001/7001/700
2/7002/7001/-1

full printable version: http://www.medscape.com/viewarticle/409738_print

ADR of the Month
September 2001 Vol. 6 No. 9
EDITORS
Michelle W. McCarthy, Pharm.D.
Anne E. Hendrick, Pharm.D.

University of Virginia Health System
Department of Pharmacy Services
Drug Information Center
PO Box 800674
Charlottesville, VA 22908-0674
http://hsc.virginia.edu/pharmacy-services/Newsletters/ADR%20of%20the%20Month/ADR
Month%209-01htm.html


Do HMG-CoA reductase inhibitors impair memory?
The Tablet, a general member benefit published by the British Columbia
Pharmacy Association, September 2001, Volume 10 no 8.
Excerpt:
Do HMG-CoA reductase inhibitors impair memory? After taking simvastatin for
a year, a 51-year-old patient developed short term memory loss, to the
extent of being unable to complete his sentences because he would forget
what he was going to say. The drug was discontinued, replaced by
pravastatin, and within one month his memory returned.14 In a separate case,
a 67-year-old woman developed impaired short-term memory, altered mood,
social impairment, cognitive impairment and dementia after one year of
atorvastatin therapy. When atorvastatin was discontinued, her memory, mood
and cognition improved completely.15 Memory impairment in a patient
receiving atorvastatin has been reported to the BC Regional ADR Centre.
REFERENCES:
14. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss.
15. King DS, Jones DW, Wofford MR et al. First report of cognitive
impairment in an elderly patient: case report. Pharmacotherapy 2001 Mar; 21:
371.

http://www.bcpharmacy.ca/publications/thetablet/pdf_version/BCPhA_Tablet-Sep2001.pdf
See page 11 of 16:

AMNESIA & STATINS

Lipitor, Thief of Memory

Dr. Duane Graveline, retired family MD, USAF Flight Surgeon, researcher in
space medicine and US Astronaut, who suffered adverse effects from Lipitor.
The book is available through Amazon.com.  Dr. Graveline maintains several
websites and is working on a second book about statin drug side effects:
www.spacedoc.net (you can start here and read about his life and his books)
http://www.spacedoc.net/lipitor_thief_of_memory.html
http://www.spacedoc.net/lipitor.htm
http://www.spacedoc.net/statin_dialogues.htm

Australian Adverse Drug Reactions Bulletin (Australia's equivalent to the
FDA)
Volume 17, Number 3, August 1998, section 3, page 3
Simvastatn is listed under "DRUGS THAT MAKE YOU FORGET"
Recognizing the 14 reports of Amnesia under that drug, .8% of the total
adverse effects for that drug.
www.health.gov.au/tga/docs/pdf/aadrbltn/aadr9808.pdf

===========

Please see also:

Mechanistic and epidemiologic considerations in the evaluation of adverse
birth outcomes following gestational exposure to statins.Am J Med Genet.
2004 Dec 15;131A(3):287-98. Edison RJ, Muenke M.Medical Genetics Branch,
National Human Genome Research Institute, National Institutes of Health,
Department of Health and Human Services, Bethesda,Maryland 20892-3717, USA."The
cholesterol-lowering "statin" drugs are contraindicated in pregnancy, but
few data exist on their safety in human gestation. We reviewed case reports
for patterns suggesting drug-related effects on prenatal development and
considered a variety of mechanisms by which such effects, if confirmed,
might occur. This uncontrolled case series included all FDA reports of
statin exposures during gestation, as well as others from the literature and
from manufacturers. Exposures and outcomes were reviewed and were tabulated
by individual drug. Age-specific rates of exposure to each drug among women
of child-bearing age were estimated. Of 214 ascertained pregnancy exposures,
70 evaluable reports remained after excluding uninformative cases. Among 31
adverse outcomes were 22 cases with structural defects, 4 cases of
intrauterine growth restriction, and 5 cases of fetal demise. There were two
principal categories of recurrent structural defects: cerivastatin and
lovastatin were a_ssociated with four reports of severe midline CNS defects;
simvastatin, lovastatin, and atorvastatin were all a_ssociated with reports
of limb deficiencies, including two similar complex lower limb defects
reported following simvastatin exposure. There were also two cases of
VACTERL a_ssociation among the limb deficiency cases. All adverse outcomes
were reported following exposure to cerivastatin, simvastatin, lovastatin,
or atorvastatin, which are lipophilic and equilibrate between maternal and
embryonic compartments. None were reported following exposure to
pravastatin, which is minimally present in the embryo. Statins reaching the
embryo may down-regulate biosynthesis of cholesterol as well as many
important metabolic intermediates, and may have secondary effects on
sterol-dependent morphogens such as Sonic Hedgehog. The reported cases
display patterns consistent with dysfunction of cholesterol biosynthesis and
Sonic Hedgehog activity. Controlled studies are needed to investigate the
teratogenicity of individual drugs in this cla_ss."PMID: 15546153 [PubMed -
in process]

Statins and risk of polyneuropathy, A case-control study
D. Gaist, MD, PhD; U. Jeppesen, MD, PhD; M. Andersen, MD, PhD; L.A. García
Rodríguez, MD, MSc;
J. Hallas, MD, PhD; and S.H. Sindrup, MD, PhD
http://213.4.18.135/87.pdf full text

Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase
inhibitor.
von Keutz E, Schluter G.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9
737641&dopt=Abstract

Institute of Toxicology, PH-Product Development, Bayer AG, Wuppertal,
Germany
Am J Cardiol. 1998 Aug 27;82(4B):11J-17J.
PMID: 9737641
"In dogs, the species most sensitive to statins, cerivastatin caused
erosions and hemorrhages in the gastrointestinal tract, bleeding in the
brain stem with fibroid degeneration of vessel walls in the choroid plexus,
and lens opacity."

Subchronic toxicity of atorvastatin, a hydroxymethylglutaryl-coenzyme A
reductase inhibitor, in beagle dogs.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8
864188&dopt=Abstract

Walsh KM, Albassam MA, Clarke DE.
Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann
Arbor, Michigan 48105, USA.
"The toxicity of atorvastatin (AT), an inhibitor of
hydroxymethylglutaryl-coenzyme A reductase (HMG), was evaluated in beagle
dogs. hemorrhage in gallbladder and brain, demyelination of optic nerve, and
skeletal muscle necrosis"

Finally, on memory loss and statins: Sworn testimony from the Baycol trial
in Corpus Christi, Texas. From the transcript of the AM Session on 03-05-03,
in the case Hollis Haltom Vs. Bayer Corporation. Testifying under oath,., in
response to the plaintiff's attorney's question, "What is your current
position at Bayer?", LAWRENCE POSNER, M.D of BAYER stated: "I'm the --  
currently I'm the head of worldwide regulatory affairs for our prescription
drug business, which means I have responsibility in somewhere between 60 and
100 countries where we sell products for registrations, compliance, things
of that nature." Excerpts from the trial transcript follow, with the Q
indicating counsel's Question, and the A indicating Dr. Posner's Answer:
Q. So there are some concerns addressed here back in 1995 about testing up
to .8. And do you know what the nature of the concern was?
A. Yes. It was related to a side effect that occurred in the brain.
Q. Of what kind of animal?
A. It occurred in the brain of dogs.
Q. Okay. So there was a side effect that occurred in dogs, and then there
was a concern about whether you wanted to go forward and test at this higher
dose level in human beings, given what you had learned about the dogs,
right?
A. That's correct.
Q. Okay. Now, did you just say, well, let's forget about these concerns and
we'll go ahead and put .8 on the market anyway, or did you do some further
analysis that was not mentioned the other day?
A. Yes. The authors of this had -- they had two concerns. One concern was
the toxicity that they found in the brain of dogs. But the other was that
they had no way to identify this and who might be at risk before it
happened. So there was no way to detect that someone was at risk for this
side effect.
[skip some testimony on other topics]
Q. Do you remember in one kind of animal there had been some studies done
that there could be a particular kind of problem with one kind of animal?
A. Oh, yeah. Yes, from the -- that's correct, from the toxicology studies.
Q. Okay. And were you able to demonstrate to your own satisfaction, to
SmithKline's satisfaction, to the FDA's satisfaction, that that particular
problem that showed up with that kind of animal is not something that
happens in human beings?
A. Yes. We did it -- we did it by explaining the toxicology data. We also
explained it on the basis of kinetic data. That actually at the higher
levels of drug, what happens is a certain amount of drug is bound to
proteins in the body that circulate; and therefore, is not -- cannot cause
side effects. And actually, a much smaller proportion of the drug is free.
And that what you corrected for that, you actually found out that the
margins of safety were in fact greater than you would predict just from the
animal data.
Q. And as you move forward then and got approval and sold Baycol from 1997
through 2001, did that problem that had shown up with that one kind of
animal ever become a problem with human beings?
A. It was actually shown with other statins as well. It wasn't unique to
cerivastatin. It was a problem -- it was identified early on with lovastatin
and some of the others. In fact, for none of the statins did it ever predict
for any clinical problem or toxicity.
Q. So these animals would have that same problem regardless of which
statin -- or at least with other statins?
A. Certainly with lovastatin it was true.
Q. But when it came time to human beings, that just wasn't something that
happened to human beings?
A. And I think today no one pays much attention to it.

Statin Adverse Effects FAQ: NERVE DAMAGE & STATINS

References (updated as of  January 7, 2005):

Statin-associated peripheral neuropathy: review of the literature.

Chong PH, Boskovich A, Stevkovic N, Bartt RE. Pharmacotherapy. 2004
Sep;24(9):1194-203. Review. PMID: 15460180 [PubMed - indexed for
MEDLINE]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15460180"Based

on epidemiologic studies as well as case reports, a risk of peripheral
neuropathy associated with statin use may exist; however, the risk appears
to be minimal. On the other hand, the benefits of statins are firmly
established. These findings should alert prescribers to a potential risk of
peripheral neuropathy in patients receiving any of the statins; that is,
statins should be considered the cause of peripheral neuropathy when other
etiologies have been excluded."  Disorder resembling Guillain-Barre syndrome
on initiation of statin therapy.Rajabally YA, Varakantam V, Abbott RJ.
Muscle Nerve. 2004 Nov;30(5):663-6. PMID: 15389662 [PubMed - indexed for
MEDLINE]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15389662"We

report a disorder resembling Guillain-Barre syndrome, occurring on
initiation of simvastatin, in a 58-year-old man, who had experienced a
similar but milder episode after starting pravastatin 6 months earlier. This
case suggests that acute polyradiculoneuropathy may represent a rare but
serious side-effect of statin treatment. It also raises the issue of the
pathophysiology of acute neuropathy on statin exposure, with a
hypersensitivity reaction resulting in an immune-mediated process being
possible instead of the hypothesized mitochondrial dysfunction in chronic
cases."  Simvastatin-induced mononeuropathy multiplex: case report.Scola RH,
Trentin AP, Germiniani FM, Piovesan EJ, Werneck LC. Arq Neuropsiquiatr. 2004
Jun;62(2B):540-2. Epub 2004 Jul 20. PMID: 15273860 [PubMed - in
process]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15273860"The

association between the use of statins and neuromuscular disease is
currently being intensely discussed. We relate a 63 years old man with
possible case of statin-induced neuropathy in a patient with dislipidemia in
use of simvastatina at high doses. The electrophysiologic studies disclosed
findings compatible with mononeuropathy multiplex, suggested by clinical
prescutation of asymmetrical numbness and weakness. More common causes of
mononeuropathy multiplex were excluded and the patient improved after the
discontinuation of the drug."
Statins and risk of polyneuropathy, A case-control study
D. Gaist, MD, PhD; U. Jeppesen, MD, PhD; M. Andersen, MD, PhD; L.A. García
Rodríguez, MD, MSc;
J. Hallas, MD, PhD; and S.H. Sindrup, MD, PhD
http://213.4.18.135/87.pdf full text

From the abstract: "The authors verified a diagnosis of idiopathic
polyneuropathy in 166 cases. The cases were classified as definite (35),
probable (54), or possible (77). The odds ratio linking idiopathic
polyneuropathy with statin use was 3.7 (95% CI 1.8 to 7.6) for all cases and
14.2 (5.3 to 38.0) for definite cases. The corresponding odds ratios in
current users were 4.6 (2.1 to 10.0) for all cases and 16.1 (5.7 to 45.4)
for definite cases. For patients treated with statins for 2 or more years
the odds ratio of definite idiopathic polyneuropathy was 26.4 (7.8 to 45.4).
CONCLUSIONS: Long-term exposure to statins may substantially increase the
risk of polyneuropathy."

Are users of lipid-lowering drugs at increased risk of peripheral
neuropathy?
David Gaist, Luis Alberto García Rodríguez · Consuelo Huerta · Jesper Hallas
· Søren H. Sindrup
http://213.4.18.135/75.pdf full text
http://213.4.18.135/76.2.pdf full text
http://213.4.18.135/87.pdf full text text

Pharmacodynamics: Statins and peripheral neuropathy
U. Jeppesen (2), D. Gaist (1)(2), T. Smith (1), S. H. Sindrup (1)(2)
(1) Department of Neurology, Odense University Hospital, DK-5000 Odense C,
Denmark Tel.: +45-6541-2474, Fax: +45-6541-3389
(2) Department of Clinical Pharmacology Odense University, Odense, Denmark
Received: 6 July 1998 / Accepted in revised form: 1 October 1998
Abstract Volume 54 Issue 11 (1999) pp 835-838
http://link.springer-ny.com/link/service/journals/00228/bibs/9054011/90540835.htm
"Within the past 3 years seven cases of reversible peripheral neuropathy
apparently caused by statins have been reported. Here we report seven
additional cases associated with long-term statin therapy, in which other
causes of neuropathy were thoroughly excluded. The neuropathy was in all
cases axonal and with affection of both thick and thin nerve fibers. The
symptoms of neuropathy persisted during an observation period lasting from
10 weeks to 1 year in four cases after statin treatment had been withdrawn.
We suggest that long-term statin treatment may be associated with chronic
peripheral neuropathy."

Association of HMG-CoA reductase inhibitors with neuropathy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
2549960&dopt=Abstract

Ann Pharmacother. 2003 Feb;37(2):274-8.
Backes JM, Howard PA.
Department of Pharmacy Practice and Lipid, Atherosclerosis, Metabolic and
LDL-Apheresis Clinic, University of Kansas Medical Center, Kansas City, KS
66160-7231, USA. jbackes@kumc.edu
"Epidemiologic studies and case reports suggest an increased risk of
peripheral neuropathy with statin drugs. The majority of cases were at least
partially reversible with drug cessation." (emphasis added)

Selenoprotein synthesis and side-effects of statins.Moosmann B, Behl C.
Lancet. 2004 Mar 13;363(9412):892-4. Review. PMID: 15031036 [PubMed -
indexed for
MEDLINE]http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15031036


"We noted that the pattern of side-effects associated with statins resembles
the pathology of selenium deficiency, and postulated that the mechanism lay
in a well established, but often overlooked, biochemical pathway--the
isopentenylation of selenocysteine-tRNA([Ser]Sec). A negative effect of
statins on selenoprotein synthesis does seem to explain many of the
enigmatic effects and side-effects of statins, in particular, statin-induced
myopathy."

Statin therapy and small fibre neuropathy: a serial electrophysiological
study.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
2639733&dopt=Abstract

Lo YL, Leoh TH, Loh LM, Tan CE.
J Neurol Sci. 2003 Apr 15;208(1-2):105-8.
Department of Neurology, Singapore General Hospital, Outram Road, Singapore.
gnrlyl@sgh.com.sg
Describes 3 patients who developed neuropathy after ONE MONTH of statin
therapy. "One patient redeveloped small and large fibre neuropathy when the
similar drug was readministered."

Peripheral Neuropathy and Lipid-Lowering Therapy
Paul E. Ziajka, MD, PhD, and Tammy Wehmeier, RN, Orlando, Fla.
Abstract: We report a case of peripheral neuropathy induced and excerbated
by several commonly used HMG-CoA reductase inhibitors including lovastatin,
simvastatin, pravastatin, and atorvastatin, and the vitamin niacin. A review
of the literature shows similar cases with individual lipid-lowering drugs,
but this case shows the cross-reactivity of the neuropathic process to
different HMG-CoA reductase inhibitors, and is the first reported case of a
peripheral neuropathy exacerbated by the use of niacin.
http://www.sma.org/smj1998/julysmj98/ziajka.pdf

Peripheral neuropathy associated with simvastatin.
Phan T, McLeod JG, Pollard JD, Peiris O, Rohan A, Halpern JP.
J Neurol Neurosurg Psychiatry. 1995 May;58(5):625-8.
PMID: 7745415 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7
745415&dopt=Abstract


"Four patients are described who developed sensorimotor neuropathy while
being treated with simvastatin and had complete or partial resolution of
clinical abnormalities after withdrawal of treatment. In one case onset was
within days of commencing treatment, but in two cases symptoms did not
develop for two years. The electrophysiological and pathological features of
the neuropathy were those of axonal degeneration. Clinical evidence of
proximal and distal weakness and muscle fasciculations and persistent
abnormalities of sensory conduction after recovery suggest the possibility
of toxic damage to anterior horn cells and dorsal root ganglia. Thirty eight
other cases with symptoms suggestive of peripheral neuropathy have been
reported to the Australian Adverse Drug Reactions Advisory Committee, 22 of
whom recovered after cessation of treatment; in five cases there was
recurrence after re-exposure to the drug. Simvastatin should be considered
among the causes of peripheral neuropathy, and the drug should be withdrawn
if patients receiving it develop muscle weakness or sensory disturbances."

Lovastatin and peripheral neuropathy.
Ahmad S.
Am Heart J. 1995 Dec;130(6):1321. No abstract available.
PMID: 7484806 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7
484806&dopt=Abstract


Vestibular vertigo and lovastatin therapy.

Ahmad S.
South Med J. 1996 Feb;89(2):257-8. No abstract available.
PMID: 8578368 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=8578368


HMG-CoA reductase inhibitor therapy and peripheral neuropathy.

Jacobs MB.
Ann Intern Med. 1994 Jun 1;120(11):970. No abstract available.
PMID: 8172444 [PubMed - indexed for MEDLINE]
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8
172444&dopt=Abstract


Medication-induced peripheral neuropathy.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
2507417&dopt=Abstract

Curr Neurol Neurosci Rep. 2003 Jan;3(1):86-92. Review.
Weimer LH.
Neurological Institute of New York, 710 West 168th Street, Unit 55, New
York, NY 10032, USA. Lhw1@columbia.edu
PMID: 12507417 [PubMed - indexed for MEDLINE]
"Although most cases demonstrate acute or subacute onset after exposure,
recent experiences with statin drugs raise the possibility of occult toxic
causes of chronic idiopathic neuropathy."

Neuropathy due to drugs.

Le Quesne PM.

In: Dyck PJ, Thomas PK, Griffin JW, et al, eds. Peripheral neuropathy. 3rd
ed. Philadelphia: Saunders, 1993:1571-1581.
(Book, no link)

> Are there any scientific studies that link cholesterol drugs (Lipitor,
> Zocor, ect) as a cause of Alzheimers?  My mother is taking Lipitor.  My
[quoted text clipped - 9 lines]
>
> Any help would be appreciated!
Alan Meyer - 22 Apr 2005 19:08 GMT
> Are there any scientific studies that link cholesterol drugs (Lipitor,
> Zocor, ect) as a cause of Alzheimers?  My mother is taking Lipitor.  My
[quoted text clipped - 9 lines]
>
> Any help would be appreciated!

There is some evidence that statins LOWER the risk of Alzheimer's.

If you do a search in pubmed
 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi

on the terms "statins" and "alzheimers" you'll see, as of today,
115 hits.

I looked at a number of them and found some claiming, based
on retrospective study of patients, that statins lower the risk
of Alzheimer's.

The theory behind all of this is still very much in a formative stage.
Some scientists think that cholesterol in the brain is one of the
causes or preconditions for Alzheimer's, and that lowering
cholesterol reduces or delays the onset of the disease.
Unfortunately however, it doesn't completely prevent the disease
from occuring.

   Alan
genileuqcaj@aol.com - 22 Apr 2005 20:28 GMT
Reading the responses to my question, I have another question.  Will
dementia caused by a statin drug respond to a medicine for Alzheimers?
Last summer we didn't reorder Mom's Exelon soon enough and ran out.  My
father wanted to see if there would be any change in Mom's behavior
without the Exelon.  Mom became combative about 3-4 times a week, and
we were all miserable.  Once she started back on her meds, she was her
usual perky (but still confused) self.
Sharon Hope - 23 Apr 2005 02:23 GMT
Typically, the treatment for statin memory loss is to stop the statin, and
then supplement with 800-1,2000mg Coenzyme Q10 per day.

You need to ask the world expert, Dr. Golomb, the question on response to
Exelon.  I urge you to email or call the UCSD Statin Study, a National
Institutes of Health
(NIH) funded study immediately.
http://medicine.ucsd.edu/statin/contactinfo.html.

Low cholesterol, by the way, is associated with violence and hostility, see
the Frequently Asked Questions below:

Statin Adverse Effects FAQ: Low Cholesterol and Aggression, Violence, Crime,
Depression, Suicide Attempts

Several published medical studies have found that low cholesterol levels
have a direct correlation with mood and behavior, particularly aggression,
violence, crime, depression, and/or suicide attempts.

Findings include:

·        The authors concluded that, among
non-African-American children, low total cholesterol is associated with
school suspension or expulsion and that low total cholesterol may be a risk
factor for aggression or a risk marker for other biologic variables that
predispose to aggression.

·        A significant increase in SERT (Serotonin transporter) activity was
detected only during the first month of simvastatin therapy. This finding
suggests that within this period some patients could be vulnerable to
depression, violence, or suicide.

·        This paper reviews early biological risk factors for violence.
These factors include . low cholesterol. A biopsychosocial violence mode is
proposed.

·        The results suggest that total cholesterol level may be a useful
biological marker for the risk of suicide in depression patients.

·        The results indicated that medication-free schizophrenic patients
have statistically significant lower serum cholesterol and leptin levels
compared with controls and the difference is obvious in suicide attempters
compared with non-suicide attempters and in violent attempters than
non-violent attempters.

·        Patients with a violent suicidal attempt have significantly lower
cholesterol levels than patients with non-violent attempts and the control
subjects. Our findings suggest that suicide attempts should not be
considered a homogeneous group. They are consistent with the theory that low
levels of cholesterol are associated with increased tendency for impulsive
behavior and aggression and contribute to a more violent pattern of suicidal
behavior.

·        . The TC (low total serum cholesterol) level seems to be a
peripheral marker with prognostic value among boys with conduct disorder and
antisocial male offenders.

·        Our results confirm previous reports of lower serum cholesterol in
attempted suicide. They are also indicative of an increased noradrenaline
turnover in subjects who attempt suicide, at least within 24 hours after the
attempt. Whether this activation precedes or follows the attempt because of
the specific stress, can not be answered at present.

·        Low cholesterol may effect serotonergic neuronal activity and some
types of 5-HT receptors, then may be related to violent behavior during
sleep.

·        These findings are consistent with the cholesterol-serotonin
hypothesis and with the substantive literature linking both aggression and
depression to depressed central serotonergic activity.

·        Adjusting for other factors, low cholesterol is associated with
increased subsequent criminal violence.

·        These findings suggest the possibility that serum cholesterol
levels may be positively associated with serotonergic receptor function. The
existence of such an association may provide an explanation for reported
increases in depression, suicide and violence in individuals with low or
lowered cholesterol.

·        Our results showed that low serum cholesterol level is associated
with the violence of the suicide attempt and not with the suicide attempt
itself. Further investigations are necessary to determine the usefulness of
this easily accessible parameter as a potential risk indicator for violent
acts such as violent suicidal behavior in susceptible individuals.

·        Men with a lower cholesterol level (< or =4.5 mmol/liter) have a
higher prevalence of depressive symptoms than those with a cholesterol level
between 6 and 7 mmol/liter. These data may be important in the ongoing
debate on the putative association between low cholesterol levels and
violent death.

Some relatively recent full abstracts:

http://aje.oupjournals.org/cgi/content/abstract/161/7/691

Association of Serum Cholesterol and History of School Suspension among
School-age Children and Adolescents in the United States
Jian Zhang1, Matthew F. Muldoon2, Robert E. McKeown3 and Steven P. Cuffe4
1 Division of Health and Family Studies, Institute for Families in Society,
University of South Carolina, Columbia, SC
2 Center for Clinical Pharmacology, University of Pittsburgh School of
Medicine, Pittsburgh, PA
3 Department of Epidemiology and Biostatistics, Arnold School of Public
Health, University of South Carolina, Columbia, SC
4 Department of Neuropsychiatry and Behavioral Science, Division of Child
and Adolescent Psychiatry, University of South Carolina School of Medicine,
Columbia, SC
Correspondence to Dr. Jian Zhang, 4770 Buford Highway, MS K-24, Atlanta, GA
30341 (e-mail: bvw2@cdc.gov).
The dietary guidelines developed for adults have been extended to children,
but the role of serum cholesterol in the neurodevelopment of children is
poorly understood. In the Third National Health and Nutrition Examination
Survey (1988-1994), serum total cholesterol was measured in 4,852 children
aged 6-16 years. Psychosocial development was evaluated by interviewing the
mother regarding the child's history of school suspension or expulsion and
difficulty in getting along with others. After adjustment for family
socioeconomic status, maternal marital status and education, children's
nutrition, and academic performance, the odds ratios of children with
various concentrations of total cholesterol showed the children to be
equally comfortable in their own peer subculture and not to be different in
the proportion that had seen a mental health professional. However,
non-African-American children with a serum total cholesterol concentration
below the 25th percentile (<145 mg/dl) were almost threefold more likely to
have been suspended or expelled from schools than their peers with total
cholesterol at or above the 25th percentile (odds ratio = 2.96, 95%
confidence interval: 1.55, 5.64). The authors concluded that, among
non-African-American children, low total cholesterol is associated with
school suspension or expulsion and that low total cholesterol may be a risk
factor for aggression or a risk marker for other biologic variables that
predispose to aggression.
---
adolescent psychology; child psychology; cholesterol; juvenile delinquency;
United States
--------------------------------------------------------------------------------
Abbreviations: CI, confidence interval; DISC, Dietary Intervention Study in
Children; NHANES III, Third National Health and Nutrition Examination
Survey; STRIP, Special Turku Coronary Risk Factor Intervention Project;
WRAT-R, Wide Range Achievement Test, Revised

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15740995


Psychiatry Res. 2005 Feb 28;133(2-3):197-203.

Cholesterol-lowering therapy evokes time-limited changes in serotonergic
transmission.
Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Starkova L, Ceska R, Papezova H.
Psychiatric Clinic, First Faculty of Medicine of Charles University, Ke
Karlovu 11, 120 00 Prague, Czech Republic; School of Public Health,
University of California at Berkeley, Berkeley, CA, USA.
A number of studies have reported an increased risk for violent deaths and
depression in subjects with reduced serum cholesterol concentrations. Links
with hypothesized impairment of serotonin neurotransmission have not been
satisfactorily tested. In this investigation, the serum and membrane
cholesterol, microviscosity of erythrocyte membranes, platelet serotonin
uptake, and clinical parameters were determined during pharmacotherapy of 17
hypercholesterolemic patients. A significant decrease in serum cholesterol
and a nonsignificant decrease in membrane cholesterol concentration were
found after 2 months of simvastatin therapy. Serotonin transporter (SERT)
activity was significantly increased following 1 month of simvastatin; the
tendency to decrease the initial increase in SERT activity was evident
following 2 months of therapy. Both membrane cholesterol and SERT activity
returned to pre-treatment levels after more than 1 year of therapy.
Microviscosity of plasma membranes, impulsivity, empathy, adventure,
sensation seeking, and depressed mood were not markedly changed. These data
indicate that long-term therapy has different effects on serotonin
transmission from short-term (1- to 2-month) therapy. A significant increase
in SERT activity was detected only during the first month of simvastatin
therapy. This finding suggests that within this period some patients could
be vulnerable to depression, violence, or suicide.
PMID: 15740995 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15680620


Int J Nurs Stud. 2005 Feb;42(2):229-41.

Biosocial bases of aggressive and violent behavior--implications for nursing
studies.
Liu J, Wuerker A.
Social Science Research Institute, University of Southern California, Los
Angeles, CA 90089-0375, USA. jianghol@usc.edu
Although aggression and violence have been increasingly viewed as a major
public health problem with a biological and health basis, it has been
under-researched in the nursing and health context. This paper reviews early
biological risk factors for violence. These factors include pregnancy/birth
complications, fetal exposure to nicotine, alcohol, and drugs, low
cholesterol, malnutrition, lead and manganese exposure, head injuries and
brain dysfunction, low arousal, low serotonin, low cortisol, and high
testosterone. A biopsychosocial violence mode is proposed. Finally, the
paper argues that nursing is ideally placed to develop a new body of
knowledge based on a biosocial perspective that can lead to more effective
prevention programs for violence.
PMID: 15680620 [PubMed - in process]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=15306143


J Affect Disord. 2004 Aug;81(2):161-6.

Clinical application of low serum cholesterol as an indicator for suicide
risk in major depression.
Kim YK, Myint AM.
Department of Psychiatry, Korea University College of Medicine, Seoul, South
Korea. yongku@korea.ac.kr
BACKGROUND: Serum total cholesterol is reported to be associated with
suicidality and violence. We explored the clinical applicability of low
serum total cholesterol as an indicator for suicide risk in major
depression. METHOD: We measured the serum cholesterol levels in 149 major
depressive disorder patients admitted to an emergency room following a
suicide attempt, in 149 non-suicidal depressive controls, and in 251 normal
controls. RESULTS: Significant differences in total serum cholesterol levels
were observed between the suicide patients and non-suicide depression
patients and between violent suicide patients and non-violent suicide
patients when age, sex, BMI and total serum protein levels were controlled.
The cutoff point of 180 mg/dl gave a high sensitivity (82%), and the cutoff
point 150 mg/dl gave a high specificity (72%). These points can be used as
discriminative cutoffs between suicidal and non-suicidal depressive
patients. LIMITATIONS: A longitudinal study is necessary to confirm the
clinical applicability of serum cholesterol as a predictive indicator of
suicide risk in depression. CONCLUSION: The results suggest that total
cholesterol level may be a useful biological marker for the risk of suicide
in depression patients.
PMID: 15306143 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=12890276


Acta Psychiatr Scand. 2003 Sep;108(3):208-14.

Serum leptin and cholesterol levels in schizophrenic patients with and
without suicide attempts.
Atmaca M, Kuloglu M, Tezcan E, Ustundag B.
Departments of Psychiatry and Clinical Biochemistry, Firat University,
School of Medicine, Elazig, Turkey. matmaca_p@yahoo.com
OBJECTIVE: Previous studies demonstrate a relationship between lipid
metabolism and suicide or impulsive-aggressive behaviours. Leptin seems to
be related with lipid metabolism. Therefore, the aim was to measure total
serum cholesterol and leptin levels in 16 medication-free schizophrenic
patients with and without suicide attempts and in 16 healthy controls.
METHOD: Subjects were assessed by using Impulsivity Rating (IRS) and
Modified Overt Aggression Scale (MOAS). RESULTS: The patients had lower
total cholesterol and leptin levels in serum compared with the controls.
Significantly lower total cholesterol and leptin levels were observed in
patients who had attempted suicide compared with those who had not. The
levels were observed to be low in violent attempters when compared with
non-violent attempters. MOAS and IRS scores were negatively correlated with
both cholesterol or leptin levels in patients. CONCLUSION: The results
indicated that medication-free schizophrenic patients have statistically
significant lower serum cholesterol and leptin levels compared with controls
and the difference is obvious in suicide attempters compared with
non-suicide attempters and in violent attempters than non-violent
attempters.
PMID: 12890276 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=12880147


Clin Chem Lab Med. 2003 Jun;41(6):821-4.

Association between increased serum cholesterol and signs of depressive
mood.
Ledochowski M, Murr C, Sperner-Unterweger B, Neurauter G, Fuchs D.
Department of Internal Medicine, Leopold-Franzens University, Innsbruck,
Austria.
Hypercholesterolemia is associated with an increased risk of atherosclerosis
and coronary heart disease. Therefore, therapeutic lowering of cholesterol
is an important preventive measure of cardiac morbidity and death. As one
side effect, cholesterol-lowering drugs appear to increase the mortality due
to suicides or violence, and low lipid concentrations were found to be
associated with trait measures of depression. We compared serum cholesterol
concentrations and the Beck Depression Rating Scale (Beck's score) in 604
otherwise healthy outpatients who visited the physician's office for a
medical health check-up; 65.4% of individuals presented with serum
cholesterol concentrations > or = 5.2 mmol/l (> 200 mg/dl) and 5.3% had
elevated Beck's score (> 19), indicative for depression. Beck's score was
higher in patients with cholesterol concentrations above the 75th percentile
(= 6.2 mmol/l; U = 31221, p < 0.02, Mann-Whitney U-test), and Beck's score
correlated with cholesterol concentrations and with age. Thus, in contrast
to the widely accepted view, in our study, higher cholesterol concentrations
were associated with signs of depressive mood. Hypercholesterolemia may not
necessarily increase the risk of depressive mood, conversely, increased
intake of fat and carbohydrates by individuals with depressive mood may
increase cholesterol levels.
PMID: 12880147 [PubMed - indexed for MEDLINE]

(SH: So, perhaps eating chocolate or other fats and carbohydrates is a
natural way to recover from depression?)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=12648892


Eur Psychiatry. 2003 Feb;18(1):23-7.

Cholesterol concentrations in violent and non-violent women suicide
attempters.
Vevera J, Zukov I, Morcinek T, Papezova H.
Psychiatric Clinic, 1st Medical Faculty, Charles University of Prague,
Prague, Czech Republic. j_vevera@hotmail.com
The aim of this study was to evaluate whether women with a history of
violent suicide attempts have lower serum cholesterol concentrations than
those who attempted suicide by non-violent methods. Our retrospective study
used a case-control design to compare serum total cholesterol concentration,
hematocrit, red blood cell count and body mass index (BMI) in women with a
history of violent (n = 19) or non-violent (n = 51) suicide attempts and of
non-suicidal controls (n = 70) matched by diagnosis and age. Analysis of
covariance (ANCOVA) with age as the covariate was used to analyze
differences in cholesterol levels in groups according to violence. Violence
was found to be a significant factor (P = 0.016). Using the Scheffe test, a
significant difference (P = 0.011) was revealed between the group of violent
and non-violent suicide attempters and between the violent suicide
attempters and the control group. Patients with a violent suicidal attempt
have significantly lower cholesterol levels than patients with non-violent
attempts and the control subjects. Our findings suggest that suicide
attempts should not be considered a homogeneous group. They are consistent
with the theory that low levels of cholesterol are associated with increased
tendency for impulsive behavior and aggression and contribute to a more
violent pattern of suicidal behavior.
PMID: 12648892 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=12056583


Eur Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):8-11.

Total serum cholesterol level, violent criminal offences, suicidal behavior,
mortality and the appearance of conduct disorder in Finnish male criminal
offenders with antisocial personality disorder.
Repo-Tiihonen E, Halonen P, Tiihonen J, Virkkunen M.
Department of Forensic Psychiatry, University of Kuopio, Niuvanniemi
Hospital, Finland. eila.tiihonen@niuva.fi
Associations between low total serum cholesterol (TC) levels and antisocial
personality disorder (ASPD), violent and suicidal behavior have been found.
We investigated the associations between TC levels, violent and suicidal
behavior, age of onset of the conduct disorder (CD) and the age of death
among 250 Finnish male criminal offenders with ASPD. The CD had begun before
the age of 10 two times more often in non-violent criminal offenders who had
lower than median TC levels. The violent criminal offenders having lower
than median TC levels were seven times more likely to die before the median
age of death in the study material. The violent offenders having lower than
median TC levels were eight times more likely to die of unnatural causes.
The mean TC level of these male offenders with ASPD was lower than that of
the general Finnish male population. Low TC levels are associated with
childhood onset type of the CD, and premature and unnatural mortality among
male offenders with ASPD. The TC level seems to be a peripheral marker with
prognostic value among boys with conduct disorder and antisocial male
offenders.
PMID: 12056583 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=12056581


Eur Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):38-43.

Biogenic amine turnover and serum cholesterol in suicide attempt.
Tripodianakis J, Markianos M, Sarantidis D, Agouridaki M.
Evangelismos General Hospital, Psychiatric Department, Athens, Greece.
tripodianakis@hotmail.com
The investigation of biological correlates of suicidal behavior is important
in searching for possible changes in neuronal systems activity related to
that behavior, so that pharmacological interventions may be proposed,
especially in high-risk subjects. In a sample of 111 subjects admitted in a
general hospital after suicide attempt, we studied the turnover of
neurotransmitters by measuring the urinary output of the main metabolites of
serotonin, dopamine and noradrenaline (5-HIAA, HVA, MHPG respectively), as
well as serum cholesterol, and compared them to those of a group of 62
healthy controls. Venous blood samples and urine samples were collected
within 24 hours of admission. Psychiatric diagnosis was made according to
DSM-IIIR criteria and assessment of suicide intent with Beck's Suicidal
Intent Scale (SIS). Fifty-four (54) subjects received the diagnosis of
adjustment disorder, 25 of depression, 16 of schizophrenia and 16 of
personality disorder. Fourteen subjects (14) had employed a violent mode of
attempt. Urinary MHPG was found significantly higher in all diagnostic
groups compared to controls. No difference was found concerning the
excretion of HVA and 5-HIAA. Serum total cholesterol was found significantly
lower both in violent and non-violent attempters compared to controls after
correcting for age. No difference in serum cholesterol or MHPG was found
between violent and non-violent attempts. Serum cholesterol and MHPG
correlated negatively, while the correlations between cholesterol and 5-HIAA
or HVA were not significant. Our results confirm previous reports of lower
serum cholesterol in attempted suicide. They are also indicative of an
increased noradrenaline turnover in subjects who attempt suicide, at least
within 24 hours after the attempt. Whether this activation precedes or
follows the attempt because of the specific stress, can not be answered at
present.
PMID: 12056581 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=11952924


Psychiatry Clin Neurosci. 2002 Apr;56(2):195-8.

Sleep-related violence and low serum cholesterol: a preliminary study.
Agargun MY, Sekeroglu MR, Kara H, Ozer OA, Tombul T, Kiran U, Selvi Y.
Department of Psychiatry, Yuzuncu Yil University School of Medicine, Van,
Turkey. mehmetyucel@turk.net
To examine whether there is a relationship between serum cholesterol level
and sleep-related violence, we evaluated 15 patients with violent behavior
during sleep (VBS) and 15 normal control subjects. The patient and control
groups were matched for sex, age, and weight. There were 13 women and two
men in each group. The patients with VBS had lower serum total cholesterol,
triglyceride, and low-density lipoprotein levels than the healthy subjects.
Low cholesterol may effect serotonergic neuronal activity and some types of
5-HT receptors, then may be related to violent behavior during sleep.
PMID: 11952924 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=11199085


J Behav Med. 2000 Dec;23(6):519-29.

Serum cholesterol concentrations and mood states in violent psychiatric
patients: an experience sampling study.
Hillbrand M, Waite BM, Miller DS, Spitz RT, Lingswiler VM.
Connecticut Valley Hospital, Whiting Forensic Division, P.O. Box 70,
Middletown, Connecticut 06457, USA. hillbrandm@ccsu.edu
The well-documented negative association between serum cholesterol and
aggressive behavior has led Kaplan to propose a cholesterol-serotonin
hypothesis of aggression. According to this hypothesis, low dietary
cholesterol intake leads to depressed central serotonergic activity, which
itself has been reported in numerous studies of violent individuals. In the
present study, 25 violent psychiatric patients participated in a
microbehavioral experience sampling procedure to examine differences in
self-reports of affective and cognitive experiences as a function of serum
cholesterol concentrations. For 7 days, they wore signaling devices that
emitted an average of seven signals a day. Following each signal, patients
filled out a mood questionnaire. Total serum cholesterol (TSC) concentration
was positively associated with measures of affect, cognitive efficiency,
activation, and sociability, suggesting a link between low TSC and
dysphoria. These findings are consistent with the cholesterol-serotonin
hypothesis and with the substantive literature linking both aggression and
depression to depressed central serotonergic activity.
PMID: 11199085 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=11104842


J Psychiatr Res. 2000 Jul-Oct;34(4-5):301-9.

Low cholesterol and violent crime.
Golomb BA, Stattin H, Mednick S.
Department of Medicine, University of California, Los Angeles, CA
92093-0995, USA. bgolomb@ucsd.edu
BACKGROUND: Community cohort studies and meta-analyses of randomized trials
have shown a relation between low or lowered cholesterol and death by
violence (homicide, suicide, accident); in primates, cholesterol reduction
has been linked to increased behavioral acts of aggression (Kaplan J, Manuck
S. The effects of fat and cholesterol on aggressive behaviour in monkeys.
Psychosom. Med 1990;52:226-7; Kaplan J, Shively C, Fontenot D, Morgan T,
Howell S, Manuck S et al. Demonstration of an association among dietary
cholesterol, central serotonergic activity, and social behaviour in monkeys.
Psychosom. Med 1994;56:479-84.). In this study we test for the first time
whether cholesterol level is related to commission of violent crimes against
others in a large community cohort. METHODS: We merged one-time cholesterol
measurements on 79,777 subjects enrolled in a health screening project in
Varmland, Sweden with subsequent police records for arrests for violent
crimes in men and women aged 24-70 at enrollment; and with information on
covariates. We performed a nested case control comparison of cholesterol in
violent criminals - defined as those with two or more crimes of violence
against others - to cholesterol in nonoffenders matched on age, enrollment
year, sex, education and alcohol, using variable-ratio matching, with a
nonparametric sign test. RESULTS: One hundred individuals met criteria for
criminal violence. Low cholesterol (below the median) was strongly
associated with criminal violence in unadjusted analysis (Men: risk ratio
1.94, P=0.002; all subjects risk ratio 2.32, P<0.001). Age emerged as a
strong confounder. Adjusting for covariates using a matching procedure,
violent criminals had significantly lower cholesterol than others identical
in age, sex, alcohol indices and education, using a nonparametric sign test
(P=0.012 all subjects; P=0.035 men). CONCLUSIONS: Adjusting for other
factors, low cholesterol is associated with increased subsequent criminal
violence.
PMID: 11104842 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=11063789


Psychiatry Res. 2000 Oct 30;96(2):167-73.

Relationship between serum cholesterol levels and
meta-chlorophenylpiperazine-induced cortisol responses in healthy men and
women.
Terao T, Nakamura J, Yoshimura R, Ohmori O, Takahashi N, Kojima H, Soeda S,
Shinkai T, Nakano H, Okuno T.
Department of Psychiatry, University of Occupational and Environmental
Health, School of Medicine, Yahatanishi-ku, 807-8555, Kitakyushu, Japan.
t-terao@med.uoeh-u.ac.jp
We investigated the effect of cholesterol on serotonergic receptor function
in 20 healthy male and 10 healthy female subjects using cortisol responses
to meta-chlorophenylpiperazine (m-CPP) neuroendocrine challenge tests.
M-CPP, a metabolite of the antidepressant trazodone, has been widely used in
psychopharmacology research as a probe of serotonin function. In the human
brain, m-CPP binds both to various serotonergic receptors, mainly 5-HT(2C),
and to alpha(2)-adrenoceptors. After an overnight fast, the subjects
received m-CPP (0.5 mg/kg) or identical placebo capsules orally in a
randomized, double blind, crossover design. Blood was obtained for
measurement of cholesterol and cortisol. In some analyses, especially in
males, there were significant positive correlations between serum
cholesterol levels and cortisol responses. These findings suggest the
possibility that serum cholesterol levels may be positively associated with
serotonergic receptor function. The existence of such an association may
provide an explanation for reported increases in depression, suicide and
violence in individuals with low or lowered cholesterol.
Publication Types:

·         Clinical Trial

·         Randomized Controlled Trial

PMID: 11063789 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=10963796


Psychiatry Res. 2000 Aug 21;95(2):103-8.

Low serum cholesterol in violent but not in non-violent suicide attempters.
Alvarez JC, Cremniter D, Gluck N, Quintin P, Leboyer M, Berlin I, Therond P,
Spreux-Varoquaux O.
Faculte de Medecine Paris-Ouest et Laboratoire de Biochimie, Hopital R.
Poincare, AP-HP, 104 Bvd R. Poincare, 92380 Garches, France.
jean-claude.alvarez@rcp.ap-hop-paris.fr
Many previous studies have suggested that low or lowered serum cholesterol
levels may increase the risk of mortality not due to somatic disease:
principally, suicide and violent death. Because violent death is rare, some
studies have investigated afterwards the relation between cholesterol levels
and either suicide attempts in psychiatric populations or violence in
criminally violent populations. However, none of these studies have compared
cholesterol levels in violent and non-violent suicide attempters. The blood
of 25 consecutive drug-free patients following a violent suicide attempt and
of 27 patients following a non-violent suicide attempt by drug overdose was
drawn in the 24 h following admission. Patients with a diagnosis of alcohol
abuse and with cholesterol-lowering therapy were excluded. Age, sex, body
mass index, psychiatric diagnosis and the physical conditions of the suicide
attempt were investigated. Thirty-two healthy subjects were used as a
control group. There were no differences between the groups in age,
frequency of psychiatric diagnoses or body mass index. There was more women
in the group of non-violent suicide attempters than in that of violent
suicide attempters (P<0.001). In analyses controlling for sex and age, the
serum cholesterol concentration was 30% lower (F(2,82)=15.8; P<0.0001) in
the group of violent suicide attempters (147+/-54 mg/dl) than in the group
of non-violent suicide attempters (209+/-38 mg/dl) or control subjects
(213+/-46 mg/dl). Our results showed that low serum cholesterol level is
associated with the violence of the suicide attempt and not with the suicide
attempt itself. Further investigations are necessary to determine the
usefulness of this easily accessible parameter as a potential risk indicator
for violent acts such as violent suicidal behavior in susceptible
individuals.
PMID: 10963796 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstra
ct&list_uids=10772398


Psychosom Med. 2000 Mar-Apr;62(2):205-11.

Higher prevalence of depressive symptoms in middle-aged men with low serum
cholesterol levels.
Steegmans PH, Hoes AW, Bak AA, van der Does E, Grobbee DE.
Department of Epidemiology, Erasmus University Medical School, Rotterdam,
The Netherlands.
OBJECTIVE: Investigators from several studies have reported a positive
relationship between low cholesterol levels and death due to violent causes
(eg, suicide and accidents), possibly mediated by depressive symptoms,
aggression or hostility, or impulsivity. We set out to establish whether
middle-aged men with chronically low cholesterol levels (< or =4.5
mmol/liter) have a higher risk of having depressive symptoms, according to
scores on the Beck Depression Inventory, compared with a reference group of
men with cholesterol levels between 6 and 7 mmol/liter. A similar comparison
was also made for measures of anger, hostility, and impulsivity. METHODS:
Cholesterol measurements were obtained as part of a population-based
cholesterol screening study in 1990-1991. These levels were remeasured in
1993-1994. Only those whose cholesterol level remained in the same range
were included in the study. Depressive symptoms were assessed by using the
Beck Depression Inventory; anger, by questionnaires based on the Spielberger
Anger Expression Scale and State-Trait Anger Scale; hostility, by the
Buss-Durkee Hostility Inventory; and impulsivity, by the Eysenck and Eysenck
Impulsivity Questionnaire. RESULTS: Men with chronically low cholesterol
levels showed a consistently higher risk of having depressive symptoms (Beck
Depression Inventory score > or =15 or > or =17) than the reference group,
even after adjusting for age, energy intake, alcohol use, and presence of
chronic diseases. No differences in anger, hostility, and impulsivity were
observed between the two groups. CONCLUSIONS: Men with a lower cholesterol
level (< or =4.5 mmol/liter) have a higher prevalence of depressive symptoms
than those with a cholesterol level between 6 and 7 mmol/liter. These data
may be important in the ongoing debate on the putative association between
low cholesterol levels and violent death.
PMID: 10772398 [PubMed - indexed for MEDLINE]

==========================================================

The foregoing abstracts are of the more recent studies, but there are many
more.  A search of the National Institutes of Health (NIH) PubMed, using the
search terms "cholesterol" + "violence" yields the following list, the
overwhelming majority of which studies indicate a positive correlation
between low cholesterol and violence or similar behaviors:

1:  Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Starkova L, Ceska R, Papezova
H.  Cholesterol-lowering therapy evokes time-limited changes in
serotonergictransmission.Psychiatry Res. 2005 Feb 28;133(2-3):197-203. PMID:
15740995 [PubMed - in process] 2:  Liu J, Wuerker A.  Biosocial bases of
aggressive and violent behavior--implications for nursingstudies.Int J Nurs
Stud. 2005 Feb;42(2):229-41. PMID: 15680620 [PubMed - in process] 3:  Kim
YK, Myint AM.  Clinical application of low serum cholesterol as an indicator
for suicide riskin major depression.J Affect Disord. 2004 Aug;81(2):161-6.
PMID: 15306143 [PubMed - indexed for MEDLINE] 4:  Atmaca M, Kuloglu M,
Tezcan E, Ustundag B.  Serum leptin and cholesterol levels in schizophrenic
patients with and withoutsuicide attempts.Acta Psychiatr Scand. 2003
Sep;108(3):208-14. PMID: 12890276 [PubMed - indexed for MEDLINE] 5:
Ledochowski M, Murr C, Sperner-Unterweger B, Neurauter G, Fuchs D.
Association between increased serum cholesterol and signs of depressive
mood.Clin Chem Lab Med. 2003 Jun;41(6):821-4. PMID: 12880147 [PubMed -
indexed for MEDLINE] 6:  Vevera J, Zukov I, Morcinek T, Papezova H.
Cholesterol concentrations in violent and non-violent women suicide
attempters.Eur Psychiatry. 2003 Feb;18(1):23-7. PMID: 12648892 [PubMed -
indexed for MEDLINE] 7:  Golaszewski T, Barr D, Pronk N.  Development of
assessment tools to measure organizational support for employeehealth.Am J
Health Behav. 2003 Jan-Feb;27(1):43-54. PMID: 12500951 [PubMed - indexed for
MEDLINE] 8:  Tochigi M, Umekage T, Otani T, Kato T, Iwanami A, Asukai N,
Sasaki T, KatoN.  Serum cholesterol, uric acid and cholinesterase in victims
of the Tokyo subwaysarin poisoning: a relation with post-traumatic stress
disorder.Neurosci Res. 2002 Nov;44(3):267-72. PMID: 12413655 [PubMed -
indexed for MEDLINE] 9:  Cantor CH.  An ecological perspective of
cholesterol.Med J Aust. 2002 Jun 3;176(11):564. No abstract available. PMID:
12064996 [PubMed - indexed for MEDLINE] 10:  Repo-Tiihonen E, Halonen P,
Tiihonen J, Virkkunen M.  Total serum cholesterol level, violent criminal
offences, suicidal behavior,mortality and the appearance of conduct disorder
in Finnish male criminaloffenders with antisocial personality disorder.Eur
Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):8-11. PMID: 12056583
[PubMed - indexed for MEDLINE] 11:  Tripodianakis J, Markianos M, Sarantidis
D, Agouridaki M.  Biogenic amine turnover and serum cholesterol in suicide
attempt.Eur Arch Psychiatry Clin Neurosci. 2002 Feb;252(1):38-43. PMID:
12056581 [PubMed - indexed for MEDLINE] 12:  Agargun MY, Sekeroglu MR, Kara
H, Ozer OA, Tombul T, Kiran U, Selvi Y.  Sleep-related violence and low
serum cholesterol: a preliminary study.Psychiatry Clin Neurosci. 2002
Apr;56(2):195-8. PMID: 11952924 [PubMed - indexed for MEDLINE] 13:  Menotti
A, Blackburn H, Kromhout D, Nissinen A, Adachi H, Lanti M.  Cardiovascular
risk factors as determinants of 25-year all-cause mortality inthe seven
countries study.Eur J Epidemiol. 2001;17(4):337-46. PMID: 11767959 [PubMed -
indexed for MEDLINE] 14:  Huang TL.  Serum cholesterol levels in mood
disorders associated with physical violence orsuicide attempts in
Taiwanese.Chang Gung Med J. 2001 Sep;24(9):563-8. PMID: 11725626 [PubMed -
indexed for MEDLINE] 15:  Terao T, Whale R.  High serum cholesterol and
suicide risk.Am J Psychiatry. 2001 May;158(5):824-5. No abstract available.
PMID: 11329428 [PubMed - indexed for MEDLINE] 16:  Davidson MH.  Safety
profiles for the HMG-CoA reductase inhibitors: treatment and trust.Drugs.
2001;61(2):197-206. Review. PMID: 11270938 [PubMed - indexed for MEDLINE]
17:  Hillbrand M, Waite BM, Miller DS, Spitz RT, Lingswiler VM.  Serum
cholesterol concentrations and mood states in violent psychiatricpatients:
an experience sampling study.J Behav Med. 2000 Dec;23(6):519-29. PMID:
11199085 [PubMed - indexed for MEDLINE] 18:  Manfredini R, Caracciolo S,
Salmi R, Boari B, Tomelli A, Gallerani M.  The association of low serum
cholesterol with depression and suicidalbehaviours: new hypotheses for the
missing link.J Int Med Res. 2000 Nov-Dec;28(6):247-57. Review. PMID:
11191718 [PubMed - indexed for MEDLINE] 19:  McAllister M.  Domestic
violence: a life-span approach to assessment and intervention.Lippincotts
Prim Care Pract. 2000 Mar-Apr;4(2):174-89; quiz 190-2. PMID: 11143628
[PubMed - indexed for MEDLINE] 20:  Muldoon MF, Manuck SB, Mendelsohn AB,
Kaplan JR, Belle SH.  Cholesterol reduction and non-illness mortality:
meta-analysis of randomisedclinical trials.BMJ. 2001 Jan 6;322(7277):11-5.
PMID: 11141142 [PubMed - indexed for MEDLINE] 21:  Golomb BA, Stattin H,
Mednick S.  Low cholesterol and violent crime.J Psychiatr Res. 2000
Jul-Oct;34(4-5):301-9. PMID: 11104842 [PubMed - indexed for MEDLINE] 22:
Stewart RA, Sharples KJ, North FM, Menkes DB, Baker J, Simes J.  Long-term
assessment of psychological well-being in a randomizedplacebo-controlled
trial of cholesterol reduction with pravastatin. The LIPIDStudy
Investigators.Arch Intern Med. 2000 Nov 13;160(20):3144-52. PMID: 11074745
[PubMed - indexed for MEDLINE] 23:  Huang T, Wu S.  Serum cholesterol levels
in paranoid and non-paranoid schizophrenia associatedwith physical violence
or suicide attempts in Taiwanese.Psychiatry Res. 2000 Oct 30;96(2):175-8.
PMID: 11063790 [PubMed - indexed for MEDLINE] 24:  Terao T, Nakamura J,
Yoshimura R, Ohmori O, Takahashi N, Kojima H, Soeda S,Shinkai T, Nakano H,
Okuno T.  Relationship between serum cholesterol levels
andmeta-chlorophenylpiperazine-induced cortisol responses in healthy men and
women.Psychiatry Res. 2000 Oct 30;96(2):167-73. PMID: 11063789 [PubMed -
indexed for MEDLINE] 25:  Alvarez JC, Cremniter D, Gluck N, Quintin P,
Leboyer M, Berlin I, TherondP, Spreux-Varoquaux O.  Low serum cholesterol in
violent but not in non-violent suicide attempters.Psychiatry Res. 2000 Aug
21;95(2):103-8. PMID: 10963796 [PubMed - indexed for MEDLINE] 26:  Steegmans
PH, Hoes AW, Bak AA, van der Does E, Grobbee DE.  Higher prevalence of
depressive symptoms in middle-aged men with low serumcholesterol
levels.Psychosom Med. 2000 Mar-Apr;62(2):205-11. PMID: 10772398 [PubMed -
indexed for MEDLINE] 27:  Tanskanen A, Vartiainen E, Tuomilehto J, Viinamaki
H, Lehtonen J, Puska P.  High serum cholesterol and risk of suicide.Am J
Psychiatry. 2000 Apr;157(4):648-50. PMID: 10739432 [PubMed - indexed for
MEDLINE] 28:  Seneviratne SL, Warnasooriya WM, Gunatilake SB, Fonseka MM,
Gunawardena MK,de Silva HJ.  Serum cholesterol concentrations in
parasuicide.Ceylon Med J. 1999 Mar;44(1):11-3. PMID: 10643091 [PubMed -
indexed for MEDLINE] 29:  Hibbeln JR, Umhau JC, George DT, Shoaf SE,
Linnoila M, Salem N Jr.  Plasma total cholesterol concentrations do not
predict cerebrospinal fluidneurotransmitter metabolites: implications for
the biophysical role of highlyunsaturated fatty acids.Am J Clin Nutr. 2000
Jan;71(1 Suppl):331S-8S. PMID: 10617992 [PubMed - indexed for MEDLINE] 30:
Steinert T, Woelfle M, Gebhardt RP.  No correlation of serum cholesterol
levels with measures of violence inpatients with schizophrenia and
non-psychotic disorders.Eur Psychiatry. 1999 Oct;14(6):346-8. PMID: 10572367
[PubMed - indexed for MEDLINE] 31:  Apter A, Laufer N, Bar-Sever M, Har-Even
D, Ofek H, Weizman A.  Serum cholesterol, suicidal tendencies, impulsivity,
aggression, and depressionin adolescent psychiatric inpatients.Biol
Psychiatry. 1999 Aug 15;46(4):532-41. PMID: 10459404 [PubMed - indexed for
MEDLINE] 32:  Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V,
Pajarinen J,Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen
PJ.  Age-dependent association of apolipoprotein E genotype with coronary
and aorticatherosclerosis in middle-aged men: an autopsy study.Circulation.
1999 Aug 10;100(6):608-13. PMID: 10441097 [PubMed - indexed for MEDLINE] 33:
Alvarez JC, Cremniter D, Lesieur P, Gregoire A, Gilton A, Macquin-Mavier
I,Jarreau C, Spreux-Varoquaux O.  Low blood cholesterol and low platelet
serotonin levels in violent suicideattempters.Biol Psychiatry. 1999 Apr
15;45(8):1066-9. PMID: 10386194 [PubMed - indexed for MEDLINE] 34:  New AS,
Sevin EM, Mitropoulou V, Reynolds D, Novotny SL, Callahan A,Trestman RL,
Siever LJ.  Serum cholesterol and impulsivity in personality
disorders.Psychiatry Res. 1999 Feb 22;85(2):145-50. PMID: 10220005 [PubMed -
indexed for MEDLINE] 35:  Klein JD, Graff CA, Santelli JS, Hedberg VA, Allan
MJ, Elster AB.  Developing quality measures for adolescent care: validity of
adolescents'self-reported receipt of preventive services.Health Serv Res.
1999 Apr;34(1 Pt 2):391-404. PMID: 10199683 [PubMed - indexed for MEDLINE]
36:  Puska P, Vartiainen E, Tuomilehto J, Salomaa V, Nissinen A.  Changes in
premature deaths in Finland: successful long-term prevention
ofcardiovascular diseases.Bull World Health Organ. 1998;76(4):419-25. PMID:
9803593 [PubMed - indexed for MEDLINE] 37:  Weinberger RF.  Cholesterol and
violence: is there a connection?Ann Intern Med. 1998 Oct 15;129(8):669-70.
No abstract available. PMID: 9786821 [PubMed - indexed for MEDLINE] 38:
Faustman WO, Ringo DL, Lindley SE.  Cholesterol and violence: is there a
connection?Ann Intern Med. 1998 Oct 15;129(8):669; author reply 669-70. No
abstractavailable. PMID: 9786820 [PubMed - indexed for MEDLINE] 39:
Goldstein MR.  Cholesterol and violence: is there a connection?Ann Intern
Med. 1998 Oct 15;129(8):668-9; author reply 669-70. No abstractavailable.
PMID: 9786819 [PubMed - indexed for MEDLINE] 40:  Nash SD.  Cholesterol and
violence: is there a connection?Ann Intern Med. 1998 Oct 15;129(8):668;
author reply 669-70. No abstractavailable. PMID: 9786818 [PubMed - indexed
for MEDLINE] 41:  Schlienger JL, Goichot B, Pradignac A.  [Cholesterolemia
and pathology: update]Rev Med Interne. 1998 Mar;19(3):180-4. Review.
French. PMID: 9775138 [PubMed - indexed for MEDLINE] 42:  Hibbeln JR, Umhau
JC, Linnoila M, George DT, Ragan PW, Shoaf SE, VaughanMR, Rawlings R, Salem
N Jr.  A replication study of violent and nonviolent subjects: cerebrospinal
fluidmetabolites of serotonin and dopamine are predicted by plasma essential
fattyacids.Biol Psychiatry. 1998 Aug 15;44(4):243-9. PMID: 9715355 [PubMed -
indexed for MEDLINE] 43:  Hibbeln JR, Linnoila M, Umhau JC, Rawlings R,
George DT, Salem N Jr.  Essential fatty acids predict metabolites of
serotonin and dopamine incerebrospinal fluid among healthy control subjects,
and early- and late-onsetalcoholics.Biol Psychiatry. 1998 Aug
15;44(4):235-42. PMID: 9715354 [PubMed - indexed for MEDLINE] 44:  Kaplan
JR, Muldoon MF, Manuck SB, Mann JJ.  Assessing the observed relationship
between low cholesterol andviolence-related mortality. Implications for
suicide risk.Ann N Y Acad Sci. 1997 Dec 29;836:57-80. Review. PMID: 9616794
[PubMed - indexed for MEDLINE] 45:  Mufti RM, Balon R, Arfken CL.  Low
cholesterol and violence.Psychiatr Serv. 1998 Feb;49(2):221-4. PMID: 9575009
[PubMed - indexed for MEDLINE] 46:  Golomb BA.  Cholesterol and violence: is
there a connection?Ann Intern Med. 1998 Mar 15;128(6):478-87. Review. PMID:
9499332 [PubMed - indexed for MEDLINE] 47:  Boston PF, Dursun SM, Reveley
MA.  Cholesterol and mental disorder.Br J Psychiatry. 1996 Dec;169(6):682-9.
Review. PMID: 8968624 [PubMed - indexed for MEDLINE] 48:  Virkkunen M,
Eggert M, Rawlings R, Linnoila M.  A prospective follow-up study of
alcoholic violent offenders and fire setters.Arch Gen Psychiatry. 1996
Jun;53(6):523-9. PMID: 8639035 [PubMed - indexed for MEDLINE] 49:  Golomb B.
Low cholesterol and violence.Arch Intern Med. 1995 Dec 11-25;155(22):2485.
No abstract available. PMID: 7503611 [PubMed - indexed for MEDLINE] 50:
Strandberg TE, Salomaa VV, Vanhanen HT, Naukkarinen VA, Sarna SJ,
MiettinenTA.  Mortality in participants and non-participants of a
multifactorial preventionstudy of cardiovascular diseases: a 28 year follow
up of the HelsinkiBusinessmen Study.Br Heart J. 1995 Oct;74(4):449-54. PMID:
7488463 [PubMed - indexed for MEDLINE] 51:  Strandberg T.  Serum cholesterol
concentrations in parasuicide. No association between lowcholesterol and
violent death.BMJ. 1995 Sep 23;311(7008):807-8. No abstract available. PMID:
7580453 [PubMed - indexed for MEDLINE] 52:  Gallerani M, Manfredini R,
Caracciolo S, Scapoli C, Molinari S, Fersini C.  Serum cholesterol
concentrations in parasuicide.BMJ. 1995 Jun 24;310(6995):1632-6. PMID:
7795448 [PubMed - indexed for MEDLINE] 53:  Schwandt P, Richter WO,
Sonnichsen AC.  Lowering high plasma cholesterol levels is not
dangerous.Arch Intern Med. 1995 May 8;155(9):985. No abstract available.
PMID: 7726707 [PubMed - indexed for MEDLINE] 54:  Penttinen J.  Hypothesis:
low serum cholesterol, suicide, and interleukin-2.Am J Epidemiol. 1995 Apr
15;141(8):716-8. PMID: 7709913 [PubMed - indexed for MEDLINE] 55:  Friedman
EH.  Neurobiology of cholesterol and violent behavior.Arch Intern Med. 1995
Mar 13;155(5):543-4. No abstract available. PMID: 7864712 [PubMed - indexed
for MEDLINE] 56:  Serjeant ME.  Cholesterol and violent behavior.Arch Intern
Med. 1995 Mar 13;155(5):544. No abstract available. PMID: 7726951 [PubMed -
indexed for MEDLINE] 57:  Toshima H, Koga Y, Menotti A, Keys A, Blackburn H,
Jacobs DR, SeccarecciaF.  The seven countries study in Japan.
Twenty-five-year experience incardiovascular and all-causes deaths.Jpn Heart
J. 1995 Mar;36(2):179-89. PMID: 7596038 [PubMed - indexed for MEDLINE] 58:
Hillbrand M, Spitz RT, Foster HG.  Serum cholesterol and aggression in
hospitalized male forensic patients.J Behav Med. 1995 Feb;18(1):33-43. PMID:
7595950 [PubMed - indexed for MEDLINE] 59:  Richter WO.  [Increased
autoaggression caused by cholesterol lowering drugs?]Fortschr Med. 1994 Dec
20;112(35-36):507-8.  German. No abstract available. PMID: 7843681 [PubMed -
indexed for MEDLINE] 60:  Paunio M, Heinonen OP, Virtamo J, Klag MJ,
Manninen V, Albanes D, ComstockGW.  HDL cholesterol and mortality in Finnish
men with special reference to alcoholintake.Circulation. 1994
Dec;90(6):2909-18. PMID: 7994838 [PubMed - indexed for MEDLINE] 61:  Boston
PF, Dursun SM, Reveley MA.  Cholesterol and violent death. Other studies
exist.BMJ. 1994 Nov 5;309(6963):1228. No abstract available. PMID: 7987161
[PubMed - indexed for MEDLINE] 62:  Hughes M.  Cholesterol and violent
death. Diets, violence, and civilization.BMJ. 1994 Nov 5;309(6963):1228. No
abstract available. PMID: 7987160 [PubMed - indexed for MEDLINE] 63:  Owens
D.  Cholesterol and violent death. Clinical importance is questionable.BMJ.
1994 Nov 5;309(6963):1228. No abstract available. PMID: 7987159 [PubMed -
indexed for MEDLINE] 64:  Kaplan JR, Shively CA, Fontenot MB, Morgan TM,
Howell SM, Manuck SB,Muldoon MF, Mann JJ.  Demonstration of an association
among dietary cholesterol, central serotonergicactivity, and social behavior
in monkeys.Psychosom Med. 1994 Nov-Dec;56(6):479-84. PMID: 7532867 [PubMed -
indexed for MEDLINE] 65:  Vartiainen E, Puska P, Pekkanen J, Tuomilehto J,
Lonnqvist J, Ehnholm C.  Serum cholesterol concentration and mortality from
accidents, suicide, andother violent causes.BMJ. 1994 Aug
13;309(6952):445-7. PMID: 7920128 [PubMed - indexed for MEDLINE] 66:
Santiago JM, Dalen JE.  Cholesterol and violent behavior.Arch Intern Med.
1994 Jun 27;154(12):1317-21. Review. Erratum in: Arch InternMed 1994 Sep
26;154(18):2047. PMID: 8002683 [PubMed - indexed for MEDLINE] 67:  Ernst E.
Cholesterol and violence: more questions than answers.Br J Hosp Med. 1994
Apr 6-19;51(7):329-30, 332-3. No abstract available. PMID: 8081561 [PubMed -
indexed for MEDLINE] 68:  Spitz RT, Hillbrand M, Foster HG Jr.  Serum
cholesterol levels and frequency of aggression.Psychol Rep. 1994
Apr;74(2):622. PMID: 8197299 [PubMed - indexed for MEDLINE] 69:  Lewis B,
Tikkanen MJ.  Low blood total cholesterol and mortality: causality,
consequence andconfounders.Am J Cardiol. 1994 Jan 1;73(1):80-5. No abstract
available. PMID: 8279383 [PubMed - indexed for MEDLINE] 70:  Dursun SM,
Reveley MA.  Low serum cholesterol and serotonin receptor subtypes.Br J
Psychiatry. 1993 Sep;163:417-8. No abstract available. PMID: 8401981
[PubMed - indexed for MEDLINE] 71:  Ong HT.  Cholesterol reduction therapy:
a double-edged knife.Med J Malaysia. 1993 Jun;48(2):107-12. Review. Erratum
in: Med J Malaysia 1993Sep;48(3):iv. PMID: 8350783 [PubMed - indexed for
MEDLINE] 72:  Gray RF, Corrigan FM, Strathdee A, Skinner ER, van Rhijn AG,
Horrobin DF.  Cholesterol metabolism and violence: a study of individuals
convicted ofviolent crimes.Neuroreport. 1993 Jun;4(6):754-6. PMID: 8347820
[PubMed - indexed for MEDLINE] 73:  Hawthon K, Cowen P, Owens D, Bond A,
Elliott M.  Low serum cholesterol and suicide.Br J Psychiatry. 1993
Jun;162:818-25. PMID: 7980726 [PubMed - indexed for MEDLINE] 74:  Epstein
FH.  Low serum cholesterol and death due to accidents, violence, or
suicide.Lancet. 1993 May 1;341(8853):1150. No abstract available. PMID:
8097829 [PubMed - indexed for MEDLINE] 75:  Schuit AJ, Dekker JM, Schouten
EG, Kok FJ.  Low serum cholesterol and death due to accidents, violence, or
suicide.Lancet. 1993 Mar 27;341(8848):827. No abstract available. Erratum
in: Lancet1993 May 1;341(8853):1150. PMID: 8096023 [PubMed - indexed for
MEDLINE] 76:  Hillbrand M, Foster HG.  Serum cholesterol levels and severity
of aggression.Psychol Rep. 1993 Feb;72(1):270. No abstract available. PMID:
8451361 [PubMed - indexed for MEDLINE] 77:  Kromhout D, Katan MB, Menotti A,
Keys A, Bloemberg B.  Serum cholesterol and long-term death rates from
suicide, accidents, orviolence. Seven Countries Study Group.Lancet. 1992 Aug
1;340(8814):317. No abstract available. PMID: 1353240 [PubMed - indexed for
MEDLINE] 78:  Ball M, Mann J.  Cholesterol lowering--the sense and the
sensationalism.N Z Med J. 1992 Jul 22;105(938):283-4. No abstract available.
PMID: 1386655 [PubMed - indexed for MEDLINE] 79:  Samuel P.  Violent death
and cholesterol reduction.Lancet. 1992 Jul 4;340(8810):50-1. No abstract
available. PMID: 1351622 [PubMed - indexed for MEDLINE] 80:  Peer DA,
Stoukides CA.  Association of low cholesterol with aggression.Ann
Pharmacother. 1992 Jun;26(6):785-6. Review. No abstract available. PMID:
1611162 [PubMed - indexed for MEDLINE] 81:  Oliver MF.  Low serum
cholesterol and suicide.Lancet. 1992 May 9;339(8802):1168-9. No abstract
available. PMID: 1349387 [PubMed - indexed for MEDLINE] 82:  Modest G.
Long-term mortality after primary prevention for cardiovascular
disease.JAMA. 1992 Apr 22-29;267(16):2184; author reply 2185-6. No abstract
available.Erratum in: JAMA 1993 Feb 3;269(5):591. PMID: 1556788 [PubMed -
indexed for MEDLINE] 83:  Engelberg H.  Low serum cholesterol and
suicide.Lancet. 1992 Mar 21;339(8795):727-9. PMID: 1347593 [PubMed - indexed
for MEDLINE] 84:  Rossouw JE, Canner PL, Hulley SB.  Deaths from injury,
violence, and suicide in secondary prevention trials ofcholesterol
lowering.N Engl J Med. 1991 Dec 19;325(25):1813. No abstract available.
PMID: 1834942 [PubMed - indexed for MEDLINE] 85:  Kaplan JR, Manuck SB,
Shively C.  The effects of fat and cholesterol on social behavior in
monkeys.Psychosom Med. 1991 Nov-Dec;53(6):634-42. PMID: 1758948 [PubMed -
indexed for MEDLINE] 86:  Pekkanen J, Poikolainen K.  [Cholesterol-lowering
drugs and violent deaths]Duodecim. 1991;107(14):1145-8.  Finnish. No
abstract available. PMID: 1670510 [PubMed - indexed for MEDLINE] 87:
Wysowski DK, Gross TP.  Deaths due to accidents and violence in two recent
trials ofcholesterol-lowering drugs.Arch Intern Med. 1990
Oct;150(10):2169-72. PMID: 2222103 [PubMed - indexed for MEDLINE] 88:  [No
authors listed]  Lowering cholesterol concentrations and mortality.BMJ. 1990
Sep 15;301(6751):552-5. No abstract available. PMID: 2271045 [PubMed -
indexed for MEDLINE] 89:  Wigle DT, Mao Y, Semenciw R, McCann C, Davies JW.
Premature deaths in Canada: impact, trends and opportunities for
prevention.Can J Public Health. 1990 Sep-Oct;81(5):376-81. Erratum in: Can J
Public Health1991 Jan-Feb;82(1):26. PMID: 2253155 [PubMed - indexed for
MEDLINE] 90:  Muldoon MF, Manuck SB, Matthews KA.  Lowering cholesterol
concentrations and mortality: a quantitative review ofprimary prevention
trials.BMJ. 1990 Aug 11;301(6747):309-14. PMID: 2144195 [PubMed - indexed
for MEDLINE] 91:  Pekkanen J, Nissinen A, Punsar S, Karvonen MJ.  Serum
cholesterol and risk of accidental or violent death in a 25-yearfollow-up.
The Finnish cohorts of the Seven Countries Study.Arch Intern Med. 1989
Jul;149(7):1589-91. PMID: 2742433 [PubMed - indexed for MEDLINE] 92:  Kivela
SL, Nissinen A, Ketola A, Punsar S, Puska P, Karvonen M.  Alcohol
consumption and mortality in aging or aged Finnish men.J Clin Epidemiol.
1989;42(1):61-8. Erratum in: J Clin Epidemiol 1989;42(7):701. PMID: 2913188
[PubMed - indexed for MEDLINE] 93:  Farchi G, Menotti A, Conti S.  Coronary
risk factors and survival probability from coronary and other causesof
death.Am J Epidemiol. 1987 Sep;126(3):400-8. PMID: 3618576 [PubMed - indexed
for MEDLINE] 94:  Virkkunen ME, Horrobin DF, Jenkins DK, Manku MS.  Plasma
phospholipid essential fatty acids and prostaglandins in
alcoholic,habitually violent, and impulsive offenders.Biol Psychiatry. 1987
Sep;22(9):1087-96. PMID: 2958095 [PubMed - indexed for MEDLINE] 95:
Gualandri V, Franceschini G, Sirtori CR, Gianfranceschi G, Orsini GB,Cerrone
A, Menotti A.  AIMilano apoprotein identification of the complete kindred
and evidence of adominant genetic transmission.Am J Hum Genet. 1985
Nov;37(6):1083-97. PMID: 3936350 [PubMed - indexed for MEDLINE] 96:
Virkkunen M.  Lipid Research Clinics Coronary Primary Prevention Trial
results.JAMA. 1985 Feb 1;253(5):635-6. No abstract available. PMID: 3968799
[PubMed - indexed for MEDLINE] 97:  Virkkunen M, Penttinen H.  Serum
cholesterol in aggressive conduct disorder: a preliminary study.Biol
Psychiatry. 1984 Mar;19(3):435-9. No abstract available. PMID: 6722234
[PubMed - indexed for MEDLINE] 98:  Virkkunen M.  Serum cholesterol levels
in homicidal offenders. A low cholesterol level isconnected with a
habitually violent tendency under the influence of
alcohol.Neuropsychobiology. 1983;10(2-3):65-9. PMID: 6674827 [PubMed -
indexed for MEDLINE] 99:  [No authors listed]  W.H.O. cooperative trial on
primary prevention of ischaemic heart disease usingclofibrate to lower serum
cholesterol: mortality follow-up. Report of theCommittee of Principal
Investigators.Lancet. 1980 Aug 23;2(8191):379-85. PMID: 6105515 [PubMed -
indexed for MEDLINE] 100:  Kozararevic D, McGee D, Vojvodic N, Racic Z,
Dawber T, Gordon T, Zukel W.  Frequency of alcohol consumption and morbidity
and mortality: The YugoslaviaCardiovascular Disease Study.Lancet. 1980 Mar
22;1(8169):613-6. PMID: 6102625 [PubMed - indexed for MEDLINE] 101:
Carruthers M, Taggart P.  Vagotonicity of violence: biochemical and cardiac
responses to violent filmsand television programmes.Br Med J. 1973 Aug
18;3(5876):384-9. No abstract available. PMID: 4730188 [PubMed - indexed for
MEDLINE] 102:  Mushin A, Morgan G.  Ocular injury in the battered baby
syndrome. Report of two cases.Br J Ophthalmol. 1971 May;55(5):343-7. No
abstract available. PMID: 5579167 [PubMed - indexed for MEDLINE]

> Reading the responses to my question, I have another question.  Will
> dementia caused by a statin drug respond to a medicine for Alzheimers?
[quoted text clipped - 3 lines]
> we were all miserable.  Once she started back on her meds, she was her
> usual perky (but still confused) self.
Karen - 23 Apr 2005 02:10 GMT
From what I've read, excess cholesterol may be implicated in Alzheimer's but
statins are known to cause Alzheimer's like symptoms in some people.  Others
have no problems with statins.  Why seems to be a mystery they haven't yet
solved.  Seems there isn't nearly as much money available to research the
adverse effects of drugs versus funding for the benefits (IMO).

The Alzheimer's like symptoms are one of those things doctors don't like to
acknowledge.  Like the link between depression and statins.  Seems some
people (particularly males) need cholesterol to keep their seratonin levels
in balance.  A friend of mine finally said he'd rather die young after
several cycles of statins and anti-depressants (and he follows a healthy
lifestyle).

Karen

> There is some evidence that statins LOWER the risk of Alzheimer's.
>
[quoted text clipped - 16 lines]
>
>     Alan
Karen - 23 Apr 2005 02:37 GMT
On re-reading this, I have to point out that blockage of blood to the brain
can also cause dementia and memory loss.

Karen

> From what I've read, excess cholesterol may be implicated in Alzheimer's but
> statins are known to cause Alzheimer's like symptoms in some people.  Others
[quoted text clipped - 31 lines]
> >
> >     Alan
Sharon Hope - 23 Apr 2005 02:17 GMT
Incorrect.  There is absolutely NO EVIDENCE that statins lower the risk of
Alzheimers.

What you have seen is a plethora of published articles speculating on the
topic.  The studies that have been published (vs the Position Papers and
Hype) all have come in as negative or inconclusive findings.

Prior to some results, one team of participating doctors published on the
difficulty of even running the study, because so many of the statin group
'washed out' of the study because of adverse effects.

The timing for of these speculative articles with titles like, "Could
statins prevent AZ?" is very suspicious, as it looks simply like marketing
spin, given it came on the heels of some popular press articles on
devastating, debilitating, disabling memory loss, amnesia, aphasia and other
cognitive damage directly attributable to statins.

See, for example, the reprint of the Smart Money Magazine article, "Lipitor,
Thief of Memory."  I have first-hand knowledge that the information in the
story is correct.
http://www.n3inc.com/SmartMoneyReprint_103003Web.pdf

See also Dr. Graveline's two books:
See also Dr. Graveline's website for his book "Lipitor, Thief of Memory,"
and his new book, "Statin Drugs Side Effects." http://www.spacedoc.net/

Then do the search on Pub Med and READ the abstracts.   NO EVIDENCE that
statins lower the risk of Alzheimers.  Then do the search on Cognitive and
read the studies that show statins CAUSE memory loss.

>> Are there any scientific studies that link cholesterol drugs (Lipitor,
>> Zocor, ect) as a cause of Alzheimers?  My mother is taking Lipitor.  My
[quoted text clipped - 30 lines]
>
>    Alan
outrider@despammed.com - 23 Apr 2005 05:23 GMT
> Are there any scientific studies that link cholesterol drugs (Lipitor,
> Zocor, ect) as a cause of Alzheimers?  My mother is taking Lipitor.  My
[quoted text clipped - 9 lines]
>
> Any help would be appreciated!

Your mother's dementia may well be caused by Lipitor (or any statin).
Mine was. I have recovered a great deal, but still not enough to return
to a career as a reporter, journalist, writer and editor.

Here is a television story about someone who experienced what you
mother may be experiencing. Further down in this thread, read Sharon
Hope's post for clinical  studies and the name of a National Institutes
of Health funded researcher in statin induced dementia, memory loss,
aphasia, and other toxic cognitive and physical damage.

http://www.cbsnews.com/stories/2004/05/24/eveningnews/main619351.shtml

Zee
no cardiovascular disease, total cholesterol 9.7
still recovering from serious statin injury
 
Sign In
Join
My Latest Posts
My Monitored Threads
My Blog
My Photo Gallery
My Profile
My Homepage

Start New Thread
Enable EMail Alerts
Rate this Thread



©2008 Advenet LLC   Privacy Policy - Terms of Use
This website includes both content owned or controlled by Advenet as well as content owned or controlled by third parties.